The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women

Results and lessons for future research

Gregory A. Plotnikoff, Kenji Watanabe, Carolyn Torkelson, June La Valleur, David M. Radosevich

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: The aim of this study was to assess the efficacy of TU-025, keishibukuryogan, a Japanese prescription herbal medicine used for hot flash management, in American women. Methods: This randomized, double-blind, placebo-controlled, phase II trial enrolled 178 postmenopausal women aged 45 to 58 years with a Mayo hot flash score greater than 28 per week who met other inclusion criteria. After a 1-week placebo run-in period, participants were randomly assigned placebo, or 7.5 g/day, or 12.5 g/day groups, for 12 weeks. Primary and secondary outcomes were measured using the Mayo Clinic Hot Flash Diary, the Greene Climacteric Index, and the Pittsburgh Sleep Quality Index. Results: At 3 months, hot flash scores, climacteric symptoms, and sleep quality improved by 34% in the placebo group, 40% in the 7.5 g/day group, and 38% in the 12.5 g/day group. (P < 0.001). However, the differences in changes between groups were not statistically significant (P = 0.990). Diarrhea unexpectedly developed in 20% of participants receiving active medication. Conclusions: For American women, unlike the clinical experience for Japanese women, TU-025 did not significantly reduce the frequency and severity of hot flash symptoms, improve climacteric symptoms, or benefit sleep quality. This study identified several potentially significant methodological factors to be considered in future scientific assessments of traditional Asian medicines.

Original languageEnglish
Pages (from-to)886-892
Number of pages7
JournalMenopause
Volume18
Issue number8
DOIs
Publication statusPublished - 2011 Aug

Fingerprint

Hot Flashes
Clinical Trials
Placebos
Sleep
Herbal Medicine
Traditional Medicine
Prescriptions
Diarrhea
keishibukuryogan

Keywords

  • Alternative medicine
  • Herbal medicine
  • Hot flash
  • Menopause

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women : Results and lessons for future research. / Plotnikoff, Gregory A.; Watanabe, Kenji; Torkelson, Carolyn; La Valleur, June; Radosevich, David M.

In: Menopause, Vol. 18, No. 8, 08.2011, p. 886-892.

Research output: Contribution to journalArticle

Plotnikoff, Gregory A. ; Watanabe, Kenji ; Torkelson, Carolyn ; La Valleur, June ; Radosevich, David M. / The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women : Results and lessons for future research. In: Menopause. 2011 ; Vol. 18, No. 8. pp. 886-892.
@article{1087af962e1d4ea7bfce8b7f02f97886,
title = "The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women: Results and lessons for future research",
abstract = "Objective: The aim of this study was to assess the efficacy of TU-025, keishibukuryogan, a Japanese prescription herbal medicine used for hot flash management, in American women. Methods: This randomized, double-blind, placebo-controlled, phase II trial enrolled 178 postmenopausal women aged 45 to 58 years with a Mayo hot flash score greater than 28 per week who met other inclusion criteria. After a 1-week placebo run-in period, participants were randomly assigned placebo, or 7.5 g/day, or 12.5 g/day groups, for 12 weeks. Primary and secondary outcomes were measured using the Mayo Clinic Hot Flash Diary, the Greene Climacteric Index, and the Pittsburgh Sleep Quality Index. Results: At 3 months, hot flash scores, climacteric symptoms, and sleep quality improved by 34{\%} in the placebo group, 40{\%} in the 7.5 g/day group, and 38{\%} in the 12.5 g/day group. (P < 0.001). However, the differences in changes between groups were not statistically significant (P = 0.990). Diarrhea unexpectedly developed in 20{\%} of participants receiving active medication. Conclusions: For American women, unlike the clinical experience for Japanese women, TU-025 did not significantly reduce the frequency and severity of hot flash symptoms, improve climacteric symptoms, or benefit sleep quality. This study identified several potentially significant methodological factors to be considered in future scientific assessments of traditional Asian medicines.",
keywords = "Alternative medicine, Herbal medicine, Hot flash, Menopause",
author = "Plotnikoff, {Gregory A.} and Kenji Watanabe and Carolyn Torkelson and {La Valleur}, June and Radosevich, {David M.}",
year = "2011",
month = "8",
doi = "10.1097/gme.0b013e31821643d9",
language = "English",
volume = "18",
pages = "886--892",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women

T2 - Results and lessons for future research

AU - Plotnikoff, Gregory A.

AU - Watanabe, Kenji

AU - Torkelson, Carolyn

AU - La Valleur, June

AU - Radosevich, David M.

PY - 2011/8

Y1 - 2011/8

N2 - Objective: The aim of this study was to assess the efficacy of TU-025, keishibukuryogan, a Japanese prescription herbal medicine used for hot flash management, in American women. Methods: This randomized, double-blind, placebo-controlled, phase II trial enrolled 178 postmenopausal women aged 45 to 58 years with a Mayo hot flash score greater than 28 per week who met other inclusion criteria. After a 1-week placebo run-in period, participants were randomly assigned placebo, or 7.5 g/day, or 12.5 g/day groups, for 12 weeks. Primary and secondary outcomes were measured using the Mayo Clinic Hot Flash Diary, the Greene Climacteric Index, and the Pittsburgh Sleep Quality Index. Results: At 3 months, hot flash scores, climacteric symptoms, and sleep quality improved by 34% in the placebo group, 40% in the 7.5 g/day group, and 38% in the 12.5 g/day group. (P < 0.001). However, the differences in changes between groups were not statistically significant (P = 0.990). Diarrhea unexpectedly developed in 20% of participants receiving active medication. Conclusions: For American women, unlike the clinical experience for Japanese women, TU-025 did not significantly reduce the frequency and severity of hot flash symptoms, improve climacteric symptoms, or benefit sleep quality. This study identified several potentially significant methodological factors to be considered in future scientific assessments of traditional Asian medicines.

AB - Objective: The aim of this study was to assess the efficacy of TU-025, keishibukuryogan, a Japanese prescription herbal medicine used for hot flash management, in American women. Methods: This randomized, double-blind, placebo-controlled, phase II trial enrolled 178 postmenopausal women aged 45 to 58 years with a Mayo hot flash score greater than 28 per week who met other inclusion criteria. After a 1-week placebo run-in period, participants were randomly assigned placebo, or 7.5 g/day, or 12.5 g/day groups, for 12 weeks. Primary and secondary outcomes were measured using the Mayo Clinic Hot Flash Diary, the Greene Climacteric Index, and the Pittsburgh Sleep Quality Index. Results: At 3 months, hot flash scores, climacteric symptoms, and sleep quality improved by 34% in the placebo group, 40% in the 7.5 g/day group, and 38% in the 12.5 g/day group. (P < 0.001). However, the differences in changes between groups were not statistically significant (P = 0.990). Diarrhea unexpectedly developed in 20% of participants receiving active medication. Conclusions: For American women, unlike the clinical experience for Japanese women, TU-025 did not significantly reduce the frequency and severity of hot flash symptoms, improve climacteric symptoms, or benefit sleep quality. This study identified several potentially significant methodological factors to be considered in future scientific assessments of traditional Asian medicines.

KW - Alternative medicine

KW - Herbal medicine

KW - Hot flash

KW - Menopause

UR - http://www.scopus.com/inward/record.url?scp=80051546925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051546925&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e31821643d9

DO - 10.1097/gme.0b013e31821643d9

M3 - Article

VL - 18

SP - 886

EP - 892

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 8

ER -